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ABSTRACT
Objectives: Primary Sjögren’s syndrome (pSS)
shares clinical features and pathogenetic mechanisms
with systemic lupus erythematosus (SLE). SLE is
associated with an increased thromboembolic risk;
however, it is unclear whether pSS patients are
susceptible to thromboembolic diseases. In this study,
we examined ex vivo blood clot formation (clot
strength, rates of clot formation and lysis) in pSS
using thromboelastography (TEG) and platelet
aggregation to common agonists using multiple
electrode aggregometry (MEA). We also investigated
the relationship between TEG/MEA parameters and
clinical/laboratory features of pSS.
Design: Case control.
Setting: Secondary care, single centre.
Participants: 34 pSS patients, 11 SLE patients and
13 healthy volunteers (all women) entered and
completed the study.
Primary and secondary outcome measures:
Primary outcomes: TEG and MEA parameters between
three subject groups. Secondary outcomes: The
relationships between TEG/MEA and clinical/laboratory
parameters analysed using bivariate correlation analysis
with corrections for multiple testing.
Results: All TEG and MEA parameters were similar for
the three subject groups. After corrections for multiple
testing, interleukin (IL)-1α and Macrophage
inflammatory proteins (MIP)-1α remain correlated
inversely with clot strength (r=−0.686, p=0.024 and r=
−0.730, p=0.012, respectively) and overall coagulability
(r=−0.640, p=0.048 and r=−0.648, p=0.048). Stepwise
regression analysis revealed that several cytokines such
as MIP-1α, IL-17a, IL-1α and Interferon (IFN)-γ may
be key predictors of clot strength and overall
coagulability in pSS.
Conclusions: Clot kinetics and platelet receptor
function are normal in pSS. Several cytokines correlate
with clot strength and overall coagulability in pSS.
INTRODUCTION
Primary Sjögren’s syndrome (pSS) and sys-
temic lupus erythematosus (SLE) share many
clinical and pathobiological features.1 In SLE,
many clinical and scientific studies have con-
firmed an increased risk of thrombosis,2 3
accelerated atherosclerosis and higher cardio-
vascular morbidity and mortality.4 To date,
data on thrombosis and thromboembolic risk
in pSS are limited.
Theander et al5 found no increase in ischae-
mic cardiovascular mortality in pSS patients
compared with the general population. The
incidence of thromboembolic events (TEEs)
in pSS patients (1.44/100 patient-years) was
less than that for SLE patients (2.9/100
patient-years).2 6 The incidence of venous
thromboembolism was higher in pSS patients
compared with the normal population (0.48
events/100 patient-years6 vs 0.07–0.1 events/
100 patient-years7–9), but the incidence of
ARTICLE SUMMARY
Article focus
▪ To examine ex vivo blood clot formation and
platelet aggregation in patients with primary
Sjögren’s syndrome (pSS).
▪ To investigate the relationship between clinical
and laboratory features of pSS and ex vivo
coagulation and platelet aggregation.
Key messages
▪ The kinetics of blood clot formation and platelet
aggregation in pSS is normal.
▪ Several cytokines such as MIP-1α, IL-17a, IL-1α
and IFN-γ may correlate with clot strength and
overall coagulability in pSS.
Strengths and limitations of this study
▪ This is the first study to examine ex vivo clot
kinetics and platelet aggregation in whole blood
of patients with pSS.
▪ The correlation between serum MIP-1α and
IL-1α and clot strength/overall coagulability is a
novel observation.
▪ The sample size was relatively small.
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arterial TEE was similar (0.96/100 vs 0.94/100 years10).
The risk of pulmonary embolism during the first year
after admission was high with pSS patients having a stan-
dardised incidence ratio of 7.4.3
Several clinical and laboratory observations support an
increased thrombotic potential in pSS. First, pSS patients
may have abnormal lipid profiles,11 accelerated athero-
sclerosis12 and increased prevalence of diabetes13 and
hypertension (unpublished observations), all of which
are risk factors for thromboembolic diseases. In add-
ition, it has been reported that the prevalence of anti-
phospholipid antibodies is increased among pSS
patients,14–18 which in turn may increase the thrombo-
embolic risk. Second, there is an increase in microparti-
cles, small membrane-bound vesicles secreted from
activated/apoptotic cells, in pSS patients compared with
controls and SLE patients.19 These microparticles are
implicated in the initiation/propagation of thrombus
and are associated with excessive thrombotic risk in
rheumatoid arthritis and SLE.19 20 Third, other factors
associated with pSS, such as elevated levels of inflamma-
tory cytokines and immunoglobulins and reduced com-
plement levels, have also been linked to thrombosis.21–23
Haemostasis is a complex process which involves
interactions between platelets, coagulation factors and
the blood vessel wall. Clot formation and resolution is
therefore dependent on platelet function, ‘coagulability’
of the blood and vascular endothelium. Various tests
can be used to assess coagulation ex vivo.
Thromboelastography (TEG) enables a functional evalu-
ation of the coagulation cascade in whole blood, from
clot formation to clot lysis,24 25 whereas multiple elec-
trode aggregometry (MEA) allows rapid assessment of
the function of specific platelet receptors in whole
blood.26 The use of whole blood has an advantage that
it mimics more closely the in vivo conditions.
In this study, we used TEG and MEA to investigate
whether ex vivo clotting is altered in pSS patients com-
pared with healthy individuals. SLE patients were used
as a disease comparator group. Additionally, we explored
the relationships between clotting parameters and the
clinical and laboratory data of pSS.
METHODS
Participants
All patients were recruited from the Freeman Hospital,
Newcastle-upon-Tyne, UK, or Newcastle University (see
online supplementary document 1), following informed
consent according to the principles of the Helsinki
Declaration. Sunderland research ethics committee has
approved the study. The inclusion/exclusion criteria are
listed in online supplementary table S1. We initially
studied 18 healthy controls, and found significant differ-
ences in many TEG parameters between male and
female volunteers (see online supplementary table S2).
Since the majority of pSS/SLE patients are women, in
order to avoid the confounding effect of gender
difference on clot kinetics, we have analysed the data
from female participants only.
TEG and MEA
Blood samples were collected using 18G needles and
vacutainer tubes containing citrate (for TEG) or hirudin
(for MEA). Clinical and laboratory data were collected
from medical records and from the UK Primary
Sjögren’s Registry (UKPSSR).27 All samples were ana-
lysed within 45 min to 3 h after collection as per manu-
facturers’ guidance.
Thromboelastography
A TEG 5000 Haemostasis Analyser (Haemoscope Inc,
USA) was used and data were analysed using the TEG
Analytical Software, V.4.1.54. Briefly, 1 ml of blood
sample was transferred to a vial containing kaolin to acti-
vate the clotting cascade. In total, 340 µl was then trans-
ferred to a TEG vial with 20 µl CaCl2 which chelates
citrate and promotes thrombogenesis. A TEG trace (see
online supplementary figure S1) was produced over
90 min. The following parameters corresponding to
various components of the clotting process were
recorded: R time, K time, α angle, maximum amplitude
(MA), LY30, LY60 and clotting index (CI).
Multiple electrode aggregometry
A multiplate analyser (Dynabyte, Munich, Germany)
with integrated software was used. Briefly, blood samples
were diluted with 0.9% saline solution (1:1), after 3 min
of incubation (37°C), the corresponding agonists
(20 µl) for four different platelet receptor pathways
(cyclooxygenase: archidonic acid; P2Y12: ADP; throm-
bin: thrombin receptor-activating peptide; glycoprotein
Ib: collagen) were added. Platelet aggregation enhances
the electrical resistance on the duplicate sensors, which
was transformed to arbitrary aggregation units for each
agonist.
Serum soluble molecules measurement
Serum levels of various soluble molecules (see online
supplementary table S3) from pSS patients (n=18) were
measured using Cytometric Bead Array (Becton
Dickinson, Oxford, UK) according to manufacturer’s
protocol. Briefly, capture beads for the corresponding
analytes were added to diluted serum samples. After 1 h
of incubation (room temperature), PE detection
reagents were added and incubated for 2 h, the samples
were then washed, resuspended and analysed with a flow
cytometer (BD LSR-II) and the FCAP Array software.
Statistical analysis
Minitab (V.16) and SPSS (V.19.0) were used for statistical
analysis. One-way analysis of variance and Kruskal-Wallis
tests were used for group comparisons of parametric
and non-parametric data. Pearson’s correlation was used
to analyse the relationships between the TEG/MEA data
and clinical/laboratory data. p Values were corrected for
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multiple testing using Benjamini-Hochberg procedure.
Stepwise regression analyses were performed using MA
or CI as dependent variable. Factor analysis was used to
identify independent factors among the cytokine data
for stepwise regression analysis to avoid the problem of
multicollinearity.
RESULTS
Cohort characteristics
Table 1 summarises the baseline characteristics for the
three subject groups. There were significant differences
between groups for age. Compared with pSS patients,
the average disease duration was longer for SLE patients
(4.6 vs 13 years, p=0.016), and a higher proportion was
taking steroids.
TEG and MEA
All TEG and MEA parameters were similar between pSS
patients, SLE patients and healthy controls (table 2).
The proportion of individuals in each subject group
with TEG/MEA parameters outside the ‘reference
ranges’ was also similar (data not shown). These obser-
vations indicate that there are no significant differences
in the clot strength, rate of clot formation and lysis and
platelet receptor function ex vivo between the three
subject groups.
Relationships between clinical/laboratory data of pSS and
TEG/MEA parameters
Several serum cytokines/chemokines (interleukin (IL)-1α,
IL-17a, IL-21, tumour necrosis factor-α, MIP-1α) and clin-
ical laboratory measurements (erythrocyte sedimentation
rate, C reactive protein, immunoglobulin M, platelet
count) correlated with some TEG/MEA parameters (see
online supplementary table S3). Upon corrections for
multiple testing, however, only MIP-1α and IL-1α remained
negatively correlated with clot strength (r=−0.730 and
−0.686; corrected p=0.012 and 0.024, respectively) and
overall coagulability (CI; r=−0.640 and −0.648; both cor-
rected p=0.048; figure 1). Stepwise regression revealed
MIP-1α and IL-1α as independent predictors for clot
strength (p=0.001, adjusted r2=0.498) and overall coagul-
ability (p=0.005, r2=0.381), respectively.
As anticipated, there were significant correlations
(table 3) between many cytokines given the known
physiological links between some of these cytokines.
However, some of these correlations were particularly
strong (eg, between IL-1α, MIP-1α, IL-17a and IL-21
(R>0.8)), suggesting potential multicollinearity which
may in turn be susceptible to over-fitting of the regres-
sion model. In order to mitigate the problem with multi-
collinearity, we first performed a factor analysis to
identify independent factors within the cytokine data
(see online supplementary table S4), and used these
factors as independent variables in stepwise regression.
For clot strength (MA), we identified factor 1 (which
was predominantly represented by IL-1α, MIP-1α and
IL-17a) being the key predictor (r=0.69, p=0.002; table
4A). For CI, the key independent predictors were factors
1 and 7 (r=0.807, p=0.021; table 4B). The latter was pre-
dominantly represented by IFN-γ. Taken together, our
data suggest that several cytokines such as MIP-1α,
IL-17a, IL-1α and IFN-γ may correlate with clot strength
and overall coagulability.
DISCUSSION
In this study, we found no significant differences in ex
vivo clot kinetics and platelet aggregation upon stimula-
tion by various agonists in whole blood between patients
with pSS, SLE and healthy volunteers. However, several
inflammatory parameters were associated with ex vivo
clotting parameters. Our findings in this population are
novel and to our knowledge not yet reported.
In 1986, Oxholm et al28 reported that platelet aggrega-
tion (using Dual Channel Payton Aggregometer) in
platelet-rich plasma of pSS patients was increased
Table 1 Demographics and clinical characteristics of the subject groups
pSS SLE Healthy controls p Values
Sample size 34 11 13
Age (years, mean (range)) 58 (30–83) 45 (20–78) 35 (22–54) <0.001
Disease duration (years, mean (range)) 4.6 (1–15) 13 (4–28) N/A 0.016
Anti-Ro/anti-La positive (number (%)) 26 (76) 4 (36) N/A 0.026
ESSDAI (mean (range)) 4.2 (0–15) N/A N/A –
ESSPRI (mean (range)) 5 (1.7–9.7) N/A N/A –
Hydroxychloroquine use (number (%)) 16 (47) 6 (54) 0 0.666
Steroid use (number (%)) 3 (9) 5 (45) 0 0.006
Antihypertensive use (number (%)) 8 (24) 2 (18) 0 0.711
Platelet count (mean±SD (range), ×109/l) 266±44 (205–436) 236±65 (136–383) N/A 0.053
Positive cardiovascular history* (number (%)) 1 (3) 0 (0) N/A 1.000
Positive thromboembolioc/pregnancy
loss (>1) history* (number (%))
1 (3) 0 (0) N/A 1.000
*Based on medical records, ESSDAI, EULAR Sjögren’s syndrome disease activity index; ESSPRI, EULAR Sjögren’s syndrome patient
reported index; pSS, Primary Sjögren’s syndrome; SLE, systemic lupus erythematosus.
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compared with healthy controls. However, there are
important differences between the study by Oxholm et al
and our study. First, the classification criteria used for
pSS patients were different. Before the AECG consensus
criteria 2002 were developed, studies of pSS used differ-
ent criteria for the disease, which has been a potential
reason for many discrepant data in pSS. AECG criteria
are arguably the most widely accepted classification cri-
teria for pSS to date. Second, Oxholm et al studied plate-
let aggregation in ‘isolation’, whereas in our study,
platelet aggregation was measured in ‘whole blood’,
which we believe is more physiologically relevant. In add-
ition, the process of platelet enrichment can activate
platelet and may introduce variability to the data. In con-
trast, the MEA method we used in this study involved
minimal handling of the samples. Third, the methods
used for measuring platelet aggregation and how the
results are presented differ between the two studies.
The three subject groups differed in age, but we
found no correlation between age and TEG/MEA para-
meters in healthy controls (see online supplementary
table S2). Since patients taking antiplatelet agents or
anticoagulants were excluded, clotting/platelet receptor
abnormalities in pSS could have been underestimated.
However, of the 639 pSS patients from the UKPSSR,
only 10% and 3% were taking aspirin/clopidigrel and
warfarin, respectively (unpublished data). The pSS
group in this study has relatively short disease duration,
but we found no correlation between disease duration
and any TEG/MEA parameters. The sample size of this
study was relatively small, but the mean/median values
of all the test parameters were remarkably similar
between the subject groups and the SDs for many TEG
parameters were small.
Since there were no significant difference in clotting
between SLE patients and healthy controls, our data
suggest that alternative mechanisms such as in vivo
factors (eg, endothelial dysfunction), traditional cardio-
vascular risk factors or other yet undefined mechanisms
may be responsible for the increased thromboembolic
risk in SLE.
Platelet number and function are important determi-
nants of TEG/MEA parameters. In this study, the plate-
let counts in the pSS group were within normal range
and there was no significant difference in platelet counts
between the pSS and SLE groups. Although there were
Table 2 TEG and MEA parameters for pSS patients, SLE patients and healthy controls
(A) TEG
TEG parameters
R (mins) K (mins)* α Angle (degrees)* MA (mm) LY30 (%)* LY60 (%) CI
pSS (n=34) 5.5±1.3 1.5±0.5 68.1±5.5 65.7±3.7 0.7±1.7 4.2±2.7 1.2±1.5
SLE (n=11) 5.0±0.8 1.5±0.5 69.0±4.4 64.6±4.0 1.2±2.2 4.9±2.6 1.6±1.1
Healthy controls (n=13) 5.3±1.2 1.5±0.4 68.8±3.2 66.2±5.3 0.7±0.8 3.6±1.3 1.4±1.7
p Value (ANOVA/Kruskal-Wallis) 0.342 0.703 0.561 0.637 0.286 0.462 0.664
(B) MEA
MEA parameters
AA (AU) ADP (AU) TRAP (AU) COL (AU)
pSS (n=34) 89.4±22.3 77.6±21.0 101.1±22.7 75.2±20.5
SLE (n=11) 93.5±26.5 71.1±21.3 96.3±33.6 77.0±24.5
Healthy controls (n=13) 85.3±33.4 69.4±27.4 88.6±35.4 72.7±27.5
p Value (Anova/Kruskal-Wallis) 0.752 0.515 0.419 0.893
Normally distributed values are presented as mean±SD. Non-normally distributed values (asterisk) are presented as median±IQR. Aggregate
unit (AU) values (mean±SD) shown for the platelet receptor agonists AA, ADP, COL and TRAP.
AA, archidonic acid; ANOVA, analysis of variance; CI, clotting index; COL, collagen; MEA, multiple electrode aggregometry; pSS, Primary
Sjögren’s syndrome; SLE, systemic lupus erythematosus; TEG, thromboelastography; TRAP, thrombin receptor-activating peptide.
Figure 1 Correlation between clinical and laboratory
parameters of primary Sjögren’s syndrome and
thromboelastography (TEG) values. (A) MIP-1α and (B)
interleukin (IL)-1α. Only variables that have statistical
significant correlations with TEG measurements after
corrections for multiple testing are shown. The lower limits of
detection for MIP-1α and IL-1α were 0.2 and 1 pg/ml,
respectively.
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marginally significant inverse correlations between plate-
let counts and Ly30 (r=−0.359, p=0.040 (uncorrected))
as well as Ly60 (r=−0.355, p=0.042 (uncorrected)) on
bivariate correlation analysis, such correlations were no
longer statistically significant on corrections for multiple
comparison (see online supplementary table S3).
Hydroxychloroquine is associated with reduced cardio-
vascular events and anti-phospholipid antibody-mediated
platelet activation in SLE.29 Since approximately half of
the pSS and SLE group was taking hydroxychloroquine,
this may mask the clotting abnormalities among the
patient groups. However, there were no significant differ-
ence in any of the TEG and MEA parameters between
patients who were receiving hydroxychloroquine treat-
ment and those who were not in this study (see online
supplementary table S5). We could not exclude,
however, that patients receiving hydroxychloroquine
therapy might have abnormal clot kinetics or platelet
aggregation prior to treatment.
The presence of antiphospholipid antibodies have
been reported in pSS patients and may contribute to
increased thromboembolic risk.14–18 In our study,
antiphospholipid antibodies were not systematically
tested in the patients although at least three pSS patients
were positive for antiphospholipid antibodies. Future
studies investigating whether the presence of antipho-
spholipid antibodies affect TEG/MEA parameters is
worthwhile.
A novel observation in this study is the negative correl-
ation between the serum levels of several proinflammatory
molecules such as MIP-1α/IL-1α and clot strength/overall
coagulability. Consistent with our findings, Ng et al30
reported serum IL-6 levels to be inversely correlated with
clot strength and CI in posthepatobiliary surgery patients.
These observations initially appeared contradictory to the
link between inflammation and increased TEEs.31
However, many of the potential mechanisms by which
inflammatory molecules promote thrombogenesis relate to
in vivo phenomena such as endothelial cell dysfunction
and tissue factor-mediated activation of coagulation.22 32
Another possibility for the inverse correlation between
inflammation and TEG parameters could be prior platelet
activation because previously activated platelets might be
less ready to participate in coagulation and platelet
Table 3 Bivariate correlations between serum cytokines and soluble molecules
Correlations (Pearson’s r value)
IL-1α MIP-1α IL-8 IFN-γ IL-6 IL-1β IL-12p70 IL-10 CD40L IL-17a TNF-α IL-21
IL-1α 1 0.832* −0.266 0.339 −0.222 −0.13 0.392 0.119 −0.366 0.823* 0.668* 0.837*
MIP-1α 0.832* 1 0.195 0.109 0.171 −0.109 0.18 0.095 −0.018 0.761* 0.608* 0.696*
IL-8 −0.266 0.195 1 −0.466 0.789* −0.071 −0.191 0.122 0.666* −0.225 −0.094 −0.217
IFN-γ 0.339 0.109 −0.466 1 −0.328 0.252 0.334 0.085 −0.538† 0.224 0.122 0.264
IL-6 −0.222 0.171 0.789* −0.328 1 0.09 −0.177 0.04 0.365 −0.168 −0.115 −0.219
IL-1β −0.13 −0.109 −0.071 0.252 0.09 1 −0.026 0.026 −0.134 0.21 −0.06 −0.191
IL-12p70 0.392 0.18 −0.191 0.334 −0.177 −0.026 1 0.571† −0.231 0.234 0.369 0.547†
IL-10 0.119 0.095 0.122 0.085 0.04 0.026 0.571† 1 0.184 0.149 0.455 0.246
CD40L −0.366 −0.018 0.666* −0.538† 0.365 −0.134 −0.231 0.184 1 −0.153 0 −0.303
IL-17a 0.823* 0.761* −0.225 0.224 −0.168 0.21 0.234 0.149 −0.153 1 0.760* 0.563†
TNF-α 0.668* 0.608* −0.094 0.122 −0.115 −0.06 0.369 0.455 0 0.760* 1 0.437
IL-21 0.837* 0.696* −0.217 0.264 −0.219 −0.191 0.547† 0.246 −0.303 0.563† 0.437 1
*Correlation is significant at the 0.01 level (two-tailed).
†Correlation is significant at the 0.05 level (two-tailed).
IL, interleukin; TNF, tumour necrosis factor.
Table 4 Identify independent predictors of clot strength and clotting index using factor analysis approach
Unstandardised
coefficients
Standardised
coefficients
Collinearity
statistics
Model B SE β t Significance Tolerance VIF
(A) Independent predictor of clot strength
(Constant) 64.382 0.615 104.746 0
REGR factor score 1 for analysis 1 −2.336 0.634 −0.69 −3.687 0.002 1 1
r=0.690, r2=0.475, adjusted r2=0.44
(B) Independent predictor of clotting index
(Constant) 0.724 0.26 2.779 0.015
REGR factor score 1 for analysis 1 −1.18 0.268 −0.694 −4.395 0.001 1 1
REGR factor score 7 for analysis 1 0.697 0.268 0.41 2.596 0.021 1 1
r=0.807, r2=0.651, adjusted r2=0.601
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aggregation compared with non-activated platelets. It is
therefore of interest that platelet activation has been linked
with an upregulation of the type I interferon signature in
SLE,33 as a similar gene signature has also been described
in the peripheral blood samples of pSS patients.34 35
However, in this study, soluble CD40L, a potential marker
of platelet activation did not correlate with the TEG/MEA
parameters. More detailed studies of the relationships
between prior platelet activation and clot kinetics and
platelet aggregation would be of interest. In TEG, clot
strength is determined by platelet number and function, as
well as cross-linking of fibrin to form a stable clot. In this
study, neither MIP-1α nor IL-1α correlated with platelet
counts (r=−0.146, p=0.575 and r=−0.130, p=0.619, respect-
ively). Fibrinogen levels were not measured and therefore
a role for MIP-1α or IL-1α in fibrin cross-linking cannot be
excluded. Low levels of CCR1, receptor for MIP-1α, are
expressed on platelets, but its function is unclear.36 An
intriguing possibility is that MIP-1α may provide a negative
feedback mechanism on platelet function. Further
research into the mechanistic link between these cytokine/
chemokine and hypocoagulability is warranted.
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